IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1325.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 23-Apr-2017
Experimental Biology 2017
Beta blocker shows cancer-fighting properties
A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer. The research could lead better ways to protect our skin from the sun.

Contact: Anne Frances Johnson
Experimental Biology 2017

Public Release: 22-Apr-2017
The International Liver CongressTM 2017
Journal of Hepatology
SIRT is better tolerated than sorafenib, but doesn't increase overall survival in HCC
Results of the SARAH trial demonstrate that SIRT resulted in median OS of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable HCC. The trial, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, further demonstrated that the cumulative incidence of radiologic progression in the liver as the first event was significantly lower in the SIRT group compared to the sorafenib group.

Contact: ILC Press Office
European Association for the Study of the Liver

Public Release: 22-Apr-2017
Experimental Biology 2017
Cancer research advances: 5 leads for better diagnosis and treatment
Featured research includes a non-invasive new screening approach for breast cancer, leads for drug discovery and insights on a cancer-protective diet.

Contact: Anne Frances Johnson
Experimental Biology 2017

Public Release: 21-Apr-2017
The International Liver CongressTM 2017
Journal of Hepatology
Nivolumab produces durable responses & long-term survival in severe liver cancer patients
Results from the CheckMate 040 study presented today found that nivolumab produces durable responses with long-term survival rates, regardless of whether or not patients were infected with Hepatitis B or C. Interim results from the study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that the overall objective response rate (ORR) was 14.5 percent and ORR by investigator assessment was 19.3 percent in sorafenib-experienced patients in the dose expansion phase of CheckMate 040.

Contact: ILC press office
European Association for the Study of the Liver

Public Release: 21-Apr-2017
NPG Asia Materials
DGIST develops 20 times faster biosensor
DGIST's research team develops technology which is 20 times faster than the existing biosensors using micromagnetic pattern of spider web. The technology can be used for early diagnosis and recurrence diagnosis of diseases such as cancer.
BioNano Health Guard Research Group, Plasma Bioscience Research Center of the Ministry of Science and ICT and Future Planning

Contact: Dahye Kim
DGIST (Daegu Gyeongbuk Institute of Science and Technology)

Public Release: 21-Apr-2017
Nature Communications
New bone-in technique tests therapies for breast cancer metastasis
A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone.

Contact: Allison Huseman
Baylor College of Medicine

Public Release: 20-Apr-2017
JAMA Oncology
Second cancers deadlier in young patients
Second cancers in children and adolescents and young adults (AYA) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found. Study will be published April 20 in JAMA Oncology.

Contact: Tricia Tomiyoshi
University of California - Davis Health System

Public Release: 20-Apr-2017
The International Liver CongressTM 2017
Journal of Hepatology
Is DAA therapy for hepatitis C associated with an increased risk of liver cancer?
According to data from studies being presented at ILC™ 2017, there remains continued debate on whether patients are at risk of developing liver cancer after achieving SVR with a DAA regimen for HCV. Investigators will present study results that show both sides of the argument -- DAA therapy is associated with higher risk of liver cancer compared with interferon-based therapy, versus there is no difference in liver cancer risk following cure with either therapy.

Contact: ILC Press Office
European Association for the Study of the Liver

Public Release: 20-Apr-2017
BJU International
Type of treatment for prostate cancer affects quality of life
Quality of life after prostate cancer treatment varies by the type of treatment patients receive, a new study reveals.

Contact: Penny Smith

Public Release: 20-Apr-2017
PLOS Computational Biology
New statistical analysis reveals thousands of rare mutations linked with cancer
Scientists have identified thousands of previously ignored genetic mutations that, although rare, likely contribute to cancer growth. The findings, which could help pave the way to new treatments, are published in PLOS Computational Biology.

Contact: Maricel G. Kann

Public Release: 20-Apr-2017
European Urology
Drug created from malaria parasite shows promise as bladder cancer treatment
A drug created from a malaria protein stopped tumor growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.

Contact: Heather Amos
University of British Columbia

Public Release: 20-Apr-2017
Journal of the American Society of Mass Spectrometry
Saiful Chowdhury named ASMS 'emerging investigator' for work linked to cancer, aging
The American Society of Mass Spectrometry has named Saiful Chowdhury, assistant professor of chemistry and biochemistry at The University of Texas at Arlington, as one of the leading emerging investigators worldwide for his work developing new techniques using mass spectrometry to differentiate protein modifications linked to cancer and aging.
Department of Chemistry and Biochemistry, University of Texas at Arlington, Shimadzu Center for Advanced Analytical Chemistry, UT System

Contact: Louisa Kellie
University of Texas at Arlington

Public Release: 20-Apr-2017
2017 ASCO Annual Meeting
World's largest clinical cancer research meeting to highlight latest advances
Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted in the official Press Program for the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Research results will be released in advance of and throughout the Annual Meeting, taking place June 2-6 in Chicago.

Contact: Alise Fisher
American Society of Clinical Oncology

Public Release: 20-Apr-2017
Science Translational Medicine
Protection for the gut barrier: New approach may prevent graft-versus-host disease
Stem cell transplants can save lives, for example in patients with leukemia. However, these treatments are not free of risks. One complication that may occur is graft-versus-host disease (GVHD), basically donor-derived immune cells attacking the recipient's body. A team at the Technical University of Munich (TUM) has identified molecular mechanisms that may protect patients against this dangerous response in the future. The key to preventing GVHD is in the gut.
Deutsche Forschungsgemeinschaft (DFG) (PO 1575/3-1 to H.P. and BS 56/1-1 to M.B.), Else-Kröner-Fresenius-Stiftung (2012_A61 and 2015_A06 to H.P.)

Contact: Paul Hellmich
Technical University of Munich (TUM)

Public Release: 19-Apr-2017
Amino acids in diet could be key to starving cancer
Cutting out certain amino acids - the building blocks of proteins -- from the diet of mice slows tumor growth and prolongs survival, according to new research published in Nature.
Cancer Research UK, European Research Council

Contact: Stephanie McClellan
Cancer Research UK

Public Release: 19-Apr-2017
Journal of Molecular Diagnostics
New blood test offers potential for faster, targeted treatment of non-small-cell lung cancer
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive tissue biopsy, which may often be unnecessary and delays treatment. A report in The Journal of Molecular Diagnostics describes a new blood test that can accurately and quickly identify genetic mutations associated with NSCLC, allowing clinicians to make earlier, individualized treatment choices -- a step forward in personalized cancer treatment.

Contact: Eileen Leahy
Elsevier Health Sciences

Public Release: 19-Apr-2017
Nutrient offers hope to stop deadly march toward cirrhosis, liver cancer
A new study suggests that one type of omega 3 fatty acid offers people who are obese or have a poor diet a chance to avoid serious liver damage.
US Department of Agriculture, National Institutes of Health

Contact: Don Jump
Oregon State University

Public Release: 19-Apr-2017
Clinical Nuclear Medicine
Noninvasive imaging test shown accurate in ruling out kidney cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT to CT or MRI increases the accuracy of kidney tumor classification. The research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.

Contact: Lauren Nelson
Johns Hopkins Medicine

Public Release: 19-Apr-2017
Scientific Reports
Study on mice demonstrates the action of strawberries against breast cancer
A study by European and Latin American researchers has shown that strawberry extract can inhibit the spread of laboratory-grown breast cancer cells, even when they are inoculated in female mice to induce tumors. However, the scientists do point out that these results from animal testing can not be extrapolated to humans.

Contact: SINC
FECYT - Spanish Foundation for Science and Technology

Public Release: 19-Apr-2017
IRCM research team discovers how immunotherapy can fight some cancers
Dr. André Veillette and his team have discovered why immunotherapy would work in some patients and not at all in others. The discovery published in the prestigious journal Nature.
Canadian Institutes of Health Research, Canadian Cancer Society Research Institute, Canada Research Chairs Program, the Natural Sciences and Engineering Research Council of Canada, Cole Foundation, RDV Foundation, Fonds de recherche du

Contact: Genevieve O'Meara
University of Montreal

Public Release: 19-Apr-2017
Cancer Discovery
Singapore scientists provide new insights on how cancers evade the immune system
A team of scientists from Singapore has discovered new ways in which cancers can escape the body's immune system. Focusing on gastric cancer (GC), the third leading cause of cancer death worldwide, the team's findings may also prove applicable to other major cancers with potential implications for how cancers might be better treated with immunotherapy, one of the most promising classes of anti-cancer drugs today.
Agency for Science Technology and Research, Duke-NUS Medical School, National Research Foundation Singapore

Contact: Yen May Ong
Duke-NUS Medical School

Public Release: 19-Apr-2017
Research paves way for improved colorectal cancer test
Researchers at Baylor College of Medicine and other institutions have identified specific types of bacteria that seem to be abundant in individuals with colorectal cancer. Using a combination of markers specific for these fecal microbes, scientists anticipate that a noninvasive, sensitive clinical diagnostic test potentially can be developed.

Contact: Jeannette Jimenez
Baylor College of Medicine

Public Release: 19-Apr-2017
JAMA Surgery
Pathologic complete response to neoadjuvant therapy in certain breast cancer patients predicts low risk for local metastases
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options.
PH and Fay Etta Robinson Distinguished Professorship in Cancer Research and a Cancer Center Support Grant from the National Institutes of Health (CA16672)

Contact: Clayton R. Boldt
University of Texas M. D. Anderson Cancer Center

Public Release: 18-Apr-2017
A potential cure for metastatic prostate cancer? Treatment combination shows early promise
In the past, all forms of metastatic prostate cancer have been considered incurable. In recent years, the FDA has approved six drugs for men with metastatic disease, all of which can increase survival. In a study published in Urology®, researchers demonstrate for the first time that an aggressive combination of systemic therapy (drug treatment) with local therapy (surgery and radiation) directed at both the primary tumor and metastasis can eliminate all detectable disease in selected patients with metastatic prostate cancer.
The Sidney Kimmel Center for Prostate and Urologic Cancers, NIH/National Cancer Institute, The Prostate Cancer Foundation, David H. Koch Fund for Prostate Cancer Research

Contact: Helene Caprari
Elsevier Health Sciences

Public Release: 18-Apr-2017
Researchers unlock an immunity 'black box'
Mapping the biological machinery of the inflammatory skin disease neutrophilic dermatosis offers multiple targets for treating inflammatory disorders.
National Institutes of Health and ALSAC

Contact: Jann Ingmire
St. Jude Children's Research Hospital

Showing releases 1-25 out of 1325.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases